McKesson's Q2 Profit Soars 361% on Strong Revenue Growth, Strategic Acquisitions

TL;DR

MCK is crushing it with massive profit gains and smart acquisitions, making it a strong buy despite increased debt.

AI Summary

McKesson Corporation reported robust financial performance for the three and six months ended September 30, 2025. Revenues for the three months increased by 10.1% to $103.15 billion from $93.65 billion in the prior year, while net income attributable to McKesson Corporation surged by 360.6% to $1.11 billion from $241 million. Diluted earnings per common share dramatically rose to $8.92 from $1.87. For the six-month period, revenues grew by 16.2% to $200.98 billion from $172.93 billion, and net income attributable to McKesson Corporation increased by 63.8% to $1.89 billion from $1.16 billion. Key business changes include the acquisition of an 80% controlling interest in PRISM Vision Holdings, LLC for $871 million on April 1, 2025, and a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC for $2.5 billion on June 2, 2025, significantly expanding its Oncology & Multispecialty segment. The company also reclassified its segment reporting structure, now including North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions ("RxTS"), and Medical-Surgical Solutions. Risks include increased long-term debt to $6.01 billion from $4.46 billion, partially due to financing these acquisitions, and a decrease in cash and cash equivalents to $4.00 billion from $5.69 billion. The strategic outlook emphasizes advancing health outcomes and making quality care more accessible and affordable through these expanded service offerings.

Why It Matters

McKesson's substantial profit and revenue growth, driven by strategic acquisitions like PRISM Vision and Core Ventures, signals a strong competitive position in the healthcare services market, particularly in oncology and multispecialty care. This expansion could lead to increased market share and enhanced service offerings for customers, potentially impacting smaller competitors. For investors, the significant increase in diluted EPS to $8.92 demonstrates strong shareholder value creation, though the rise in long-term debt from $4.46 billion to $6.01 billion warrants attention. Employees within the newly acquired entities will see integration into a larger, diversified healthcare leader, potentially offering new opportunities.

Risk Assessment

Risk Level: medium — The risk level is medium due to the significant increase in long-term debt from $4.46 billion as of March 31, 2025, to $6.01 billion as of September 30, 2025, primarily to finance acquisitions. Additionally, cash and cash equivalents decreased from $5.69 billion to $4.00 billion over the same period, indicating substantial cash outflow for these strategic moves.

Analyst Insight

Investors should consider McKesson's strong earnings growth and strategic acquisitions as positive indicators for future performance. While the increased debt is a factor, the company's ability to integrate these new businesses and leverage its expanded market presence will be key. Monitor debt levels and cash flow in upcoming quarters.

Financial Highlights

debt To Equity

N/A

revenue

$103.15B

operating Margin

1.36%

total Assets

$84.16B

total Debt

$6.01B

net Income

$1.11B

eps

$8.92

gross Margin

3.43%

cash Position

$4.00B

revenue Growth

+10.1%

Revenue Breakdown

Key Numbers

• $103.15B — Revenues (Increased 10.1% for the three months ended September 30, 2025, compared to $93.65 billion in 2024.)
• $1.11B — Net income attributable to McKesson Corporation (Increased 360.6% for the three months ended September 30, 2025, compared to $241 million in 2024.)
• $8.92 — Diluted Earnings Per Common Share (Increased from $1.87 for the three months ended September 30, 2025, compared to 2024.)
• $200.98B — Six-month Revenues (Increased 16.2% for the six months ended September 30, 2025, compared to $172.93 billion in 2024.)
• $1.89B — Six-month Net income attributable to McKesson Corporation (Increased 63.8% for the six months ended September 30, 2025, compared to $1.16 billion in 2024.)
• $871M — PRISM Vision Acquisition Cost (Cash payment for 80% controlling interest on April 1, 2025.)
• $2.5B — Core Ventures Acquisition Cost (Cash payment for 70% controlling interest on June 2, 2025.)
• $6.01B — Long-term Debt (Increased from $4.46 billion as of March 31, 2025, reflecting financing for acquisitions.)
• $4.00B — Cash and Cash Equivalents (Decreased from $5.69 billion as of March 31, 2025, due to acquisition spending.)
• 123.4M — Shares Outstanding (As of October 31, 2025, indicating share count for EPS calculation.)

Key Players & Entities

• MCKESSON CORP (company) — registrant
• PRISM Vision Holdings, LLC (company) — acquired company
• Community Oncology Revitalization Enterprise Ventures, LLC (company) — acquired company
• Florida Cancer Specialists & Research Institute, LLC (company) — partner in Core Ventures
• New York Stock Exchange (regulator) — exchange where MCK is listed
• U.S. Securities and Exchange Commission (regulator) — regulatory body for filing
• $103.15 billion (dollar_amount) — Q2 2025 revenues
• $1.11 billion (dollar_amount) — Q2 2025 net income attributable to McKesson Corporation
• $8.92 (dollar_amount) — Q2 2025 diluted EPS
• $2.5 billion (dollar_amount) — acquisition cost for Core Ventures

FAQ

Risk Factors

• Increased Debt Load [medium — financial]: Long-term debt increased to $6.01 billion from $4.46 billion, partly to finance acquisitions. This raises financial leverage and interest expense risk.
• Reduced Cash Reserves [medium — financial]: Cash and cash equivalents decreased to $4.00 billion from $5.69 billion, indicating significant cash outflow for acquisitions and potentially reducing liquidity for unforeseen events.
• Integration of Acquisitions [high — operational]: The successful integration of PRISM Vision Holdings and Community Oncology Revitalization Enterprise Ventures is critical. Failure to integrate could lead to operational disruptions and failure to realize expected synergies.
• Healthcare Regulatory Environment [high — regulatory]: As a major pharmaceutical distributor, McKesson is subject to extensive and evolving healthcare regulations, including pricing, reimbursement, and drug distribution laws, which could impact operations and profitability.
• Competition in Healthcare Services [medium — market]: The company operates in a competitive landscape with other large distributors and increasingly specialized service providers. Maintaining market share and pricing power requires continuous innovation and efficiency.
• Litigation and Claims [medium — legal]: The company faces ongoing claims and litigation, as indicated by 'Claims and litigation charges, net' in the statements. Adverse outcomes could result in significant financial penalties.

Industry Context

McKesson operates in the highly competitive pharmaceutical distribution and healthcare services industry. Key trends include increasing consolidation, the growing importance of specialty pharmaceuticals (especially oncology), and a focus on value-based care models. Companies are investing in technology and data analytics to improve supply chain efficiency and patient outcomes.

Regulatory Implications

McKesson faces significant regulatory scrutiny in the pharmaceutical supply chain, including compliance with drug pricing, distribution practices, and opioid settlement agreements. Changes in healthcare policy, such as Medicare Part D reforms or drug price negotiations, could materially impact revenue and profitability.

What Investors Should Do

1. Monitor acquisition integration progress
2. Assess debt management strategy
3. Analyze segment performance post-restructuring
4. Evaluate cash flow generation and liquidity

Key Dates

• 2025-04-01: Acquisition of 80% controlling interest in PRISM Vision Holdings, LLC — Expands service offerings and market reach, particularly in vision care, contributing to the Oncology & Multispecialty segment.
• 2025-06-02: Acquisition of 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC — Significantly strengthens McKesson's position in the growing oncology market, enhancing its Oncology & Multispecialty segment capabilities.
• 2025-09-30: End of Q2 Fiscal Year 2025 — Period for which the condensed consolidated financial statements are reported, showing strong revenue and net income growth.
• 2025-10-31: Shares Outstanding Date — Indicates the share count (123.4M) used for EPS calculations, relevant for understanding per-share profitability.

Glossary

Noncontrolling Interests

Represents the portion of equity in a subsidiary that is not attributable to the parent company. It's the ownership stake held by external shareholders. (McKesson reports net income attributable to noncontrolling interests, indicating that some acquired entities are not wholly owned, impacting consolidated net income.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net identifiable assets. It represents brand reputation, customer relationships, etc. (Goodwill increased significantly to $11.28 billion from $10.02 billion, primarily due to the recent acquisitions, highlighting the strategic importance of these deals.)

Intangible Assets, Net

Assets that lack physical substance but have economic value, such as patents, trademarks, and customer lists. They are amortized over their useful lives. (Intangible assets increased substantially to $4.22 billion from $1.46 billion, reflecting the value of acquired intellectual property and contracts from PRISM Vision and Core Ventures.)

Operating Income

A company's gross profit minus its operating expenses. It reflects the profitability of a company's core business operations. (Operating income more than doubled to $1.407 billion for the quarter, indicating improved operational efficiency and revenue growth.)

Diluted Earnings Per Common Share (EPS)

A measure of profitability that divides net income by the total number of diluted shares outstanding. It accounts for all potential dilutive securities like stock options and convertible bonds. (Diluted EPS surged to $8.92 from $1.87, a significant increase driven by higher net income and a slight decrease in weighted-average shares outstanding.)

Weighted-average common shares outstanding

The average number of a company's outstanding common shares over a specific period, used to calculate EPS. Diluted EPS considers potential shares from options and convertible securities. (The decrease in diluted weighted-average shares outstanding from 129.3 million in 2024 to 124.4 million in 2025 for the three-month period contributed to the higher EPS.)

Redeemable Noncontrolling Interests

Represents equity in a subsidiary that is redeemable by the holder, often at a specified price or based on a formula, and is presented outside of permanent equity. (This line item indicates potential future cash outflows or equity dilution if these interests are redeemed.)

Year-Over-Year Comparison

McKesson has demonstrated significant top-line growth, with revenues increasing by 10.1% to $103.15 billion for the quarter and 16.2% for the six months. Net income attributable to McKesson Corporation saw a dramatic surge of 360.6% for the quarter, driven by strong operational performance and potentially favorable one-time items or improved cost management. Diluted EPS also rose substantially. However, this growth was accompanied by increased long-term debt and a reduction in cash reserves, reflecting the financial impact of strategic acquisitions.

Key Financial Figures

• $0.01 — nge on which registered) Common stock, $0.01 par value MCK New York Stock Exchange

Filing Documents

• mck-20250930.htm (10-Q) — 2012KB
• mck_exhibit311x930202510-q.htm (EX-31.1) — 10KB
• mck_exhibit312x930202510-q.htm (EX-31.2) — 10KB
• mck_exhibit32x930202510-q.htm (EX-32) — 9KB
• mck-20250930_g1.jpg (GRAPHIC) — 11KB
• 0000927653-25-000140.txt ( ) — 10757KB
• mck-20250930.xsd (EX-101.SCH) — 60KB
• mck-20250930_cal.xml (EX-101.CAL) — 77KB
• mck-20250930_def.xml (EX-101.DEF) — 412KB
• mck-20250930_lab.xml (EX-101.LAB) — 753KB
• mck-20250930_pre.xml (EX-101.PRE) — 603KB
• mck-20250930_htm.xml (XML) — 1879KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION 1 Condensed Consolidated Financial Statements Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Comprehensive Income for the three and six months ended September 30, 2025 and 2024 4 Condensed Consolidated Balance Sheets as of September 30, 2025 and March 31, 2025 5 Condensed Consolidated Statements of Stockholders' Deficit for the three and six months ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2025 and 2024 8 Financial Notes 9 Note 1 - Significant Accounting Policies 9 Note 2 - Business Acquisitions and Divestitures 10 Note 3 - Restructuring, Impairment, and Related Charges, Net 13 Note 4 - Income Taxes 15 Note 5 - Redeemable Noncontrolling Interests and Noncontrolling Interests 16 Note 6 - Earnings Per Common Share 18 Note 7 - Goodwill and Intangible Assets, Net 19 Note 8 - Debt and Financing Activities 21 Note 9 - Hedging Activities 23 Note 10 - Fair Value Measurements 23 Note 11 - Commitments and Contingent Liabilities 25 Note 12 - Stockholders' Deficit 28 Note 13 - Segments of Business 32 2 Management's Discussion and Analysis of Financial Condition and Results of Operations 36 3 Quantitative and Qualitative Disclosures About Market Risk 51 4 Controls and Procedures 52

—OTHER INFORMATION

PART II—OTHER INFORMATION 1 Legal Proceedings 52 1A Risk Factors 52 2 Unregistered Sales of Equity Securities and Use of Proceeds 52 3 Defaults Upon Senior Securities 53 4 Mine Safety Disclosures 53 5 Other Information 53 6 Exhibits 54

Signatures

Signatures 55 2 Table of Contents McKESSON CORPORATION

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In millions, except per share amounts) (Unaudited) Three Months Ended September 30, Six Months Ended September 30, 2025 2024 2025 2024 Revenues $ 103,150 $ 93,651 $ 200,977 $ 172,934 Cost of sales ( 99,608 ) ( 90,403 ) ( 194,156 ) ( 166,534 ) Gross profit 3,542 3,248 6,821 6,400 Selling, distribution, general, and administrative expenses ( 2,074 ) ( 2,503 ) ( 4,270 ) ( 4,504 ) Claims and litigation charges, net 2 4 2 ( 108 ) Restructuring, impairment, and related charges, net ( 63 ) ( 171 ) ( 110 ) ( 181 ) Total operating expenses ( 2,135 ) ( 2,670 ) ( 4,378 ) ( 4,793 ) Operating income 1,407 578 2,443 1,607 Other income, net 62 34 126 164 Interest expense ( 74 ) ( 78 ) ( 123 ) ( 153 ) Income before income taxes 1,395 534 2,446 1,618 Income tax expense ( 232 ) ( 247 ) ( 452 ) ( 371 ) Net income 1,163 287 1,994 1,247 Net income attributable to noncontrolling interests ( 53 ) ( 46 ) ( 100 ) ( 91 ) Net income attributable to McKesson Corporation $ 1,110 $ 241 $ 1,894 $ 1,156 Earnings per common share attributable to McKesson Corporation Diluted $ 8.92 $ 1.87 $ 15.16 $ 8.89 Basic $ 8.95 $ 1.88 $ 15.22 $ 8.94 Weighted-average common shares outstanding Diluted 124.4 129.3 124.9 130.0 Basic 124.0 128.7 124.5 129.3 See Financial Notes 3 Table of Contents McKESSON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (In millions) (Unaudited) Three Months Ended September 30, Six Months Ended September 30, 2025 2024 2025 2024 Net income $ 1,163 $ 287 $ 1,994 $ 1,247 Other comprehensive (loss) income, net of tax Foreign currency translation adjustments ( 5 ) 34 16 3 Unrealized gain (loss) on cash flow and other hedges ( 5 ) ( 9 ) 9 ( 9 ) Changes in retirement-related benefit plans — ( 2 ) ( 1 ) ( 3 ) Other comprehensive (loss) income, net of tax ( 10 ) 23 24 ( 9 ) Comprehensive income 1,153 310 2,018 1,

View Full Filing

View this 10-Q filing on SEC EDGAR